deltatrials
Completed PHASE3 NCT00272779

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections
Interventions ATV LPV RTV Tenofovi-Emtricitabine (TDF/FTC) tablet
Updated 7 times since 2017 Last updated: Apr 7, 2011 Started: Nov 30, 2005 Primary completion: Jun 30, 2007 Completion: Oct 31, 2008

A PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 7 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain, Berlin, Germany, Bloemfontein, South Africa, Bogotá, Colombia, Bonn, Germany, Bruges, Belgium, Buenos Aires, Argentina, Campinas, Brazil, Capital Federal, Argentina, Carlton, Australia and 69 more location s